2. Academic Validation
  3. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant

  • J Med Chem. 2010 Jun 24;53(12):4701-19. doi: 10.1021/jm100395q.
Wei-Sheng Huang 1,  Chester A Metcalf,  Raji Sundaramoorthi,  Yihan Wang,  Dong Zou,  R Mathew Thomas,  Xiaotian Zhu,  Lisi Cai,  David Wen,  Shuangying Liu,  Jan Romero,  Jiwei Qi,  Ingrid Chen,  Geetha Banda,  Scott P Lentini,  Sasmita Das,  Qihong Xu,  Jeff Keats,  Frank Wang,  Scott Wardwell,  Yaoyu Ning,  Joseph T Snodgrass,  Marc I Broudy,  Karin Russian,  Tianjun Zhou,  Lois Commodore,  Narayana I Narasimhan,  Qurish K Mohemmad,  John Iuliucci,  Victor M Rivera,  David C Dalgarno,  Tomi K Sawyer,  Tim Clackson,  William C Shakespeare
Affiliations

Affiliation

  • 1 ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, USA. wei-sheng.huang@ariad.com
PMID: 20513156 DOI: 10.1021/jm100395q
Abstract

In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pan-inhibitors of Bcr-Abl, including the T315I mutation. A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain. Extensive SAR studies led to the discovery of development candidate 20g (AP24534), which inhibited the kinase activity of both native Bcr-Abl and the T315I mutant with low nM IC(50)s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines. Daily oral administration of 20g significantly prolonged survival of mice injected intravenously with Bcr-Abl(T315I) expressing Ba/F3 cells. These data, coupled with a favorable ADME profile, support the potential of 20g to be an effective treatment for CML, including patients refractory to all currently approved therapies.

Figures